About
Founder of for-profit (Corvium, Sample6) and Not-for-profit ventures (BiotechStart.org)…
Articles by Michael
-
Food Recalls by the Numbers: Who’s Been Hit Hardest?
Food Recalls by the Numbers: Who’s Been Hit Hardest?
By Michael Koeris
-
Recovering from a Food Recall: How to Communicate with the Public
Recovering from a Food Recall: How to Communicate with the Public
By Michael Koeris
-
The Food Recall Domino Effect: How to Prevent the First One From Falling
The Food Recall Domino Effect: How to Prevent the First One From Falling
By Michael Koeris
Activity
-
Strong agree Seemay Chou - we need to do better in the sampling of life! Data is the key to understanding. I want to live in a world where we don’t…
Strong agree Seemay Chou - we need to do better in the sampling of life! Data is the key to understanding. I want to live in a world where we don’t…
Shared by Michael Koeris
-
Important point. Small gain further up yields massive downstream impact.
Important point. Small gain further up yields massive downstream impact.
Shared by Michael Koeris
-
Why would anyone leave a scientific career to go build ... mouse tech? 90.4% of drugs fail in humans. It costs $2.3B and takes 12 years to get a…
Why would anyone leave a scientific career to go build ... mouse tech? 90.4% of drugs fail in humans. It costs $2.3B and takes 12 years to get a…
Liked by Michael Koeris
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
Activities and Societies: Visiting scientist in the Synthetic Biology Research Group w/ Prof. Tim Lu in the Research Laboratory of Electronics, Department of Electrical Engineering and Computer Science.
-
Activities and Societies: Sigma Xi research honor society, Alpha Chi Sigma professional chemistry fraternity, MIT European Club - Vice President, European Career Fair - Chair
-
Activities and Societies: Alpha Chi Sigma, MIT European Club, MIT European Career Fair, MIT soccer
-
Licenses & Certifications
Publications
-
Sample6 DETECT/L: An In-plant, In-shift, Enrichment-free Listeria Environmental Assay
Journal of the AOAC International
-
Advancing bacteriophage-based microbial diagnostics with synthetic biology
Trends in Biotechnology
Synthetic biology is an emerging engineering field focused on designing artificial biological systems with novel functionalities for use in therapeutics, basic science, biotechnology, and diagnostics [1,2]. Continuous advancements in DNA synthesis and sequencing technologies coupled with new techniques for genomic modification and assembly have opened the door for harnessing the power and diversity of biology for applications. For example, natural bacteriophage products, such as ListShield…
Synthetic biology is an emerging engineering field focused on designing artificial biological systems with novel functionalities for use in therapeutics, basic science, biotechnology, and diagnostics [1,2]. Continuous advancements in DNA synthesis and sequencing technologies coupled with new techniques for genomic modification and assembly have opened the door for harnessing the power and diversity of biology for applications. For example, natural bacteriophage products, such as ListShield (Intralytix) and Agriphage (Omnilytics), are commercially available for reducing unwanted bacterial contamination. Natural bacteriophages can be genetically modified to deliver engineered payloads into bacteria, thus selectively functionalizing target bacterial populations to produce active biomolecules. This strategy can endow bacteriophages with the ability to efficiently destroy bacterial biofilms or increase the bactericidal efficacy of antibiotics used in combination with phages by many orders of magnitude [3]. In addition, bacteriophages can be engineered as near-real-time microbial diagnostics by using them to transform target bacteria into factories for detectable molecules (Figure 1A)[4].
Other authors -
-
The next generation of bacteriophage therapy
Current Opinion in Microbiology
Bacteriophage therapy for bacterial infections is a concept with an extensive but controversial history. There has been a recent resurgence of interest into bacteriophages owing to the increasing incidence of antibiotic resistance and virulent bacterial pathogens. Despite these efforts, bacteriophage therapy remains an underutilized option in Western medicine due to challenges such as regulation, limited host range, bacterial resistance to phages, manufacturing, side effects of bacterial lysis,…
Bacteriophage therapy for bacterial infections is a concept with an extensive but controversial history. There has been a recent resurgence of interest into bacteriophages owing to the increasing incidence of antibiotic resistance and virulent bacterial pathogens. Despite these efforts, bacteriophage therapy remains an underutilized option in Western medicine due to challenges such as regulation, limited host range, bacterial resistance to phages, manufacturing, side effects of bacterial lysis, and delivery. Recent advances in biotechnology, bacterial diagnostics, macromolecule delivery, and synthetic biology may help to overcome these technical hurdles. These research efforts must be coupled with practical and rigorous approaches at academic, commercial, and regulatory levels in order to successfully advance bacteriophage therapy into clinical settings.
Other authors -
Patents
-
Codon optimized recombinant phage and methods of using same
Issued US 10,039,795
Composition and methods for the detection of one or more target microbe(s) are provided. Compositions of the disclosure include at least one recombinant phage capable of infecting a target microbe, said phage comprising at least a capsid protein sequence, a ribosome binding site, and a codon-optimized marker. Compositions of the disclosure may further include an aqueous solution that enhances the ability to detect marker expression upon phage infection of the target microbe. In some embodiments…
Composition and methods for the detection of one or more target microbe(s) are provided. Compositions of the disclosure include at least one recombinant phage capable of infecting a target microbe, said phage comprising at least a capsid protein sequence, a ribosome binding site, and a codon-optimized marker. Compositions of the disclosure may further include an aqueous solution that enhances the ability to detect marker expression upon phage infection of the target microbe. In some embodiments the target microbe include is Listeria.
Other inventors -
-
Phage-based bacterial detection assay
Issued US 9,828,625
Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of…
Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of such phage and articles of manufacture comprising such phage, among other things.
Other inventors -
-
Methods of making recombinant phage, compositions and articles of manufacture of same for bacterial detection
Issued US 9,340,817
Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of…
Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of such phage and articles of manufacture comprising such phage, among other things.
Other inventors -
-
RECOMBINANT PHAGE AND METHODS
Issued US 9234227
This disclosure provided methods of cloning a phage genome. Also provided are methods of making a recombinant phage genome. In some embodiments the phage genome is engineered to comprise a heterologous nucleic acid sequence, for example a sequence comprising an open reading frame. In some embodiments the phage genome is cloned in a yeast artificial chromosome. Recombinant phage genomes and recombinant phage are also provided. In some embodiments the methods are high throughput methods such as…
This disclosure provided methods of cloning a phage genome. Also provided are methods of making a recombinant phage genome. In some embodiments the phage genome is engineered to comprise a heterologous nucleic acid sequence, for example a sequence comprising an open reading frame. In some embodiments the phage genome is cloned in a yeast artificial chromosome. Recombinant phage genomes and recombinant phage are also provided. In some embodiments the methods are high throughput methods such as methods of making a plurality of recombinant phage genomes or recombinant phage. Collections of recombinant phage genomes and recombinant phage are also provided.
Other inventors -
-
PHAGE-BASED BACTERIAL DETECTION ASSAY
Filed US 20150004595
Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of…
Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of such phage and articles of manufacture comprising such phage, among other things.
Other inventors -
-
Recombinant Phage and Bacterial Detection Methods
Filed US 20140302487
Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of…
Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of such phage and articles of manufacture comprising such phage, among other things.
Other inventors -
-
SYSTEM FOR ON-SITE ENVIRONMENT MONITORING
Filed US 20140046722
Methods and systems are provided herein for monitoring pathogens in various environments and on various items, wherein data from monitoring is trackable, analyzable and comparable versus various standards or thresholds. The methods and systems disclosed herein also include a platform for managing the detection and reporting of pathogens across a number of locations within a number of environments, and using such detection for a wide variety of purposes.
Other inventors -
-
Bacteriophages expressing antimicrobial peptides and uses thereof
Filed US 2010026357
The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enymes or fragments thereof for targeting a broad spectum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of…
The present invention is generally related to engineered bacteriophages expressing antimicrobial peptides or lytic enymes or fragments thereof for targeting a broad spectum of bacterial hosts, and for the long-term suppression of bacterial phage resistance for reducing bacterial infections. In some embodiments, bacteriophages express antimicrobial peptides or antimicrobial polypeptides (e.g. phage lytic enzymes) which are secreted from the host bacteria, or alternatively released upon lysis of the bacterial host cell. Aspects of the present invention also relate to the use of the engineered bacteriophages for the reduction of bacterial infections, both in a subject or for bioremediation purposes, in clinical settings and wound healing.
Other inventors -
Projects
-
NSF SBIR Phase I A/B Award
Conceptualized project, wrote successful grant application, managed communication with stakeholder, and oversaw implementation.
Project was delivered on time and within budget.Other creators -
Honors & Awards
-
Barry M. Portnoy Immigrant Entrepreneur of the Year Award in the Life Sciences
The Immigrant Learning Center
https://www.ilctr.org/wp-content/uploads/2018/05/5-7-18-Immigrant-EntrepreneurAwards.-Press-Release.pdf
As the co-founder and CEO of Sample6, Michael Koeris’ mission is to secure the global food supply chain
by changing and improving the way food production is tested for bacterial pathogens. The synthetic
biology-based technology he and his team developed can detect dangerous pathogens in the food supply
chain, which currently cause one in five Americans to get sick or die every…https://www.ilctr.org/wp-content/uploads/2018/05/5-7-18-Immigrant-EntrepreneurAwards.-Press-Release.pdf
As the co-founder and CEO of Sample6, Michael Koeris’ mission is to secure the global food supply chain
by changing and improving the way food production is tested for bacterial pathogens. The synthetic
biology-based technology he and his team developed can detect dangerous pathogens in the food supply
chain, which currently cause one in five Americans to get sick or die every year, and catch them before food
reaches the market. The diagnostics and software inventions they created have the potential to shift the
industry from a reactive safety model to a proactive one through prediction. His innovation already helps
customers like Unilever secure their food production, and it can be more broadly applied to reduce hospital
acquired infections.
Koeris also co-founded BiotechStart.org, a not-for-profit geared toward helping more biotech startups build
their businesses faster. The organization is a fast-growing network of business builders and experts that is
helping guide and fuel the next generation of biotech startups.
Koeris credited his success to the local community saying, “The thread that runs through the biotech scene
here in Boston and that binds it together tightly is one of community! Immigrants are accepted with open
arms into the scientific and biotech entrepreneurial community.” He also acknowledged rancor and
negativity toward immigrants at a national level, but said, “This negativity is counterbalanced by the
positivity of shows of support, generosity, openness, support and altruism I observe in daily interactions
between entrepreneurs, between immigrants and former immigrants.” -
DAAD Doctoral Fellowship
Deutscher Akademischer Austauschdienst e.V.
-
DAAD Masters Fellowship
Deutscher Akademischer Austauschdienst e.V.
Languages
-
English
Native or bilingual proficiency
-
German
Native or bilingual proficiency
-
Hungarian
Elementary proficiency
-
Spanish
Elementary proficiency
Recommendations received
6 people have recommended Michael
Join now to viewMore activity by Michael
-
“Imperial, Oxford, and Cambridge produce world-class engineers. Yet post-graduation, their trajectory is an economic tragedy - and a hidden arbitrage…
“Imperial, Oxford, and Cambridge produce world-class engineers. Yet post-graduation, their trajectory is an economic tragedy - and a hidden arbitrage…
Liked by Michael Koeris
-
A lot of people have rightly praised Hugh's acting masterclass in #DeadpoolAndWolverine. How did he do it? Talent, yes. Commitment, yes. But also a…
A lot of people have rightly praised Hugh's acting masterclass in #DeadpoolAndWolverine. How did he do it? Talent, yes. Commitment, yes. But also a…
Liked by Michael Koeris
-
The NVIDIA Healthcare team just made two foundation models available as NVDA inference microservices (NIMs). Diffdock, a predictive model for how…
The NVIDIA Healthcare team just made two foundation models available as NVDA inference microservices (NIMs). Diffdock, a predictive model for how…
Liked by Michael Koeris
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More